Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.70 |
| ▸ | MAOA | P21397 | 5/20 | 0.70 |
| ▸ | BCL2 | P10415 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | RECQL | P46063 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | APEX1 | P27695 | 2/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.70 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.70 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695846 | 1.00 | TTR (1.00) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL1507679 | 1.00 | TTR (1.00) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL30695849 | 1.00 | TTR (1.00) | TTRMEN1MAPTKMT2AMCL1 | |
| Quinalizarin SCHEMBL6746696 | 0.91 | TTR (0.82) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL9350283 | 0.86 | TTR (0.76) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL29543816 | 0.86 | TTR (0.75) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL13064957 | 0.85 | TTR (0.74) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL6906327 | 0.84 | TTR (0.72) | TTRMEN1MAPTKMT2AMCL1 | |
| SCHEMBL2772226 | 0.84 | MAPT (0.86) | TTRMEN1MAPTKMT2AMCL1 | |
| Athraquinones A SCHEMBL18614 | 0.82 | MAPT (1.00) | TTRMEN1MAPTKMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| WO-2021042001-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| US-4602913-A | Use of hydroxyanthraquinones for the coloration of human keratin fibres | L'OREAL (FR) | 1986-07-29 | — | — | US | claimed |
| US-4425404-A | MULTILAYER, PROTECTIVE COATINGS | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1984-01-10 | — | — | US | claimed |
| JP-60136533-A | — | — | None | — | — | JP | disclosed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250377301-A1 | STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE | FREISTAAT BAYERN LUDWIG MAXIMILIANS UNIV MUENCHEN (DE) | 2025-12-11 | — | — | US | disclosed |
| US-4425404-A | MULTILAYER, PROTECTIVE COATINGS | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1984-01-10 | — | — | US | disclosed |
| EP-0093194-A2 | Magnetic recording medium | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1983-11-09 | — | — | EP | disclosed |
| US-4181545-A | POT LIFE OF HYDROXY POLYBUTADIENE | UNITED TECHNOLOGIES CORPORATION (US) | 1980-01-01 | — | — | US | disclosed |
| US-4084983-A | ALUMINUM FLAKES ON A COATING OF ALUMINUM HYDROXIDE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | TTR 2423/4885MEN1 1711/4885MAPT 3926/4885 |
| US-20250377301-A1 | STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE | CRY1, MKI67, IK | TTR 754/4885MEN1 1974/4885MAPT 1613/4885 |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | TTR 3357/4885MEN1 2055/4885MAPT 2071/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | TTR 4671/4885MEN1 1906/4885MAPT 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.